Simon is a passionate drug discoverer and an advisor to the Medicxi investment team. He is the founder of Levicept, a Medicxi portfolio company developing a novel biologic (LEVI-04) for the treatment of osteoarthritis.
Simon has over 25 years of pharmaceutical drug development experience and is the inventor of a broad spectrum of patents. Prior to joining Medicxi, he worked at Pfizer and contributed to the discovery of several molecules across numerous therapeutic areas (Pain, Cardiovascular, Metabolic Diseases, Urology and biomarker discovery) which achieved clinical proof of concept and beyond. These included the SGLT-2 inhibitor (STEGLATRO) for diabetes, Gabapetin for overactive bladder, Tanezumab for bladder pain and Reboxetine for stress-induced urinary incontinence.
Simon received a PhD in Physiology from La Trobe University, Australia and conducted postdoctoral research at Austin Hospital, Melbourne and at the Babraham Institute, Cambridge.